Gilead Sciences, Inc. (GILD) announced on Monday that its late-stage study showed a combination of its drug Trodelvy with Merck's (MRK) immuno-oncology agent Keytruda significantly improved ...

Gilead Sciences (NASDAQ:GILD) announced Saturday that its antibody-drug conjugate Trodelvy, in combination with Merck’s (NYSE:MRK) immunotherapy Keytruda, cut the risk of disease progression or ...

CHICAGO — A treatment that combines two different types of cancer-fighting medicines — Gilead Sciences’ Trodelvy with Merck’s Keytruda — reduced the risk of tumor progression by more ...

The use of Trodelvy plus Keytruda in patients with first-line PD-L1+ metastatic TNBC and Trodelvy as monotherapy in patients with first-line metastatic TNBC who are not candidates for PD-1/PD-L1 ...

May 31 (Reuters) - Gilead Sciences' (GILD.O) Trodelvy in combination with Merck's (MRK.N) blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35 ...

Trodelvy + Keytruda improved progression-free survival over chemo + Keytruda in PD-L1+ metastatic TNBC. No new safety signals reported in ASCENT-04; overall survival trends will be tracked with ...

Gilead Sciences, Inc. today announced positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that Trodelvy ® plus Keytruda ® significantly improved progression-free ...

With Trodelvy losing its luster and sales slowing in Gilead’s cell therapy department, the company’s stated goal to have a third of its revenue from oncology by 2030 could be in jeopardy.

Trodelvy was granted accelerated approval for metastatic urothelial cancer in 2021 based on tumor response rate and duration of response data from the global Phase 2, single-arm TROPHY-U-01 study.

Gilead Sciences' Trodelvy failed to improve survival for patients with advanced bladder cancer and only modestly extended the lives of previously treated patients with late-stage lung cancer in a ...

(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial ...